PT  - JOURNAL ARTICLE
AU  - Puckelwartz, Megan J.
AU  - Pesce, Lorenzo L.
AU  - Hernandez, Edgar J.
AU  - Webster, Gregory
AU  - Dellefave-Castillo, Lisa M.
AU  - Russell, Mark W.
AU  - Geisler, Sarah S.
AU  - Kearns, Samuel D.
AU  - Etheridge, Felix K
AU  - Etheridge, Susan P.
AU  - Monroe, Tanner O.
AU  - Pottinger, Tess D.
AU  - Kannankeril, Prince J.
AU  - Shoemaker, M. Benjamin
AU  - Fountain, Darlene
AU  - Roden, Dan M.
AU  - MacLeod, Heather
AU  - Burns, Kristin M.
AU  - Yandell, Mark
AU  - Tristani-Firouzi, Martin
AU  - George, Alfred L.
AU  - McNally, Elizabeth M.
TI  - The impact of damaging epilepsy and cardiac genetic variant burden in sudden death in the young
AID  - 10.1101/2023.03.27.23287711
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.03.27.23287711
4099  - http://medrxiv.org/content/early/2023/03/29/2023.03.27.23287711.short
4100  - http://medrxiv.org/content/early/2023/03/29/2023.03.27.23287711.full
AB  - Background Sudden unexpected death in children is a tragic event. Understanding the genetics of sudden death in the young (SDY) enables family counseling and cascade screening. The objective of this study was to characterize genetic variation in an SDY cohort using whole genome sequencing.Methods The SDY Case Registry is a National Institutes of Health/Centers for Disease Control surveillance effort to discern the prevalence, causes, and risk factors for SDY. The SDY Case Registry prospectively collected clinical data and DNA biospecimens from SDY cases <20 years of age. SDY cases were collected from medical examiner and coroner offices spanning 13 US jurisdictions from 2015-2019. The cohort included 211 children (mean age 1 year; range 0-20 years), determined to have died suddenly and unexpectedly and in whom DNA biospecimens and next-of-kin consent were ascertained. A control cohort consisted of 211 randomly sampled, sex-and ancestry-matched individuals from the 1000 Genomes Project. Genetic variation was evaluated in epilepsy, cardiomyopathy and arrhythmia genes in the SDY and control cohorts. American College of Medical Genetics/Genomics guidelines were used to classify variants as pathogenic or likely pathogenic. Additionally, genetic variation predicted to be damaging was identified using a Bayesian-based artificial intelligence (AI) tool.Results The SDY cohort was 42% European, 30% African, 17% Hispanic, and 11% with mixed ancestries, and 39% female. Six percent of the cohort was found to harbor a pathogenic or likely pathogenic genetic variant in an epilepsy, cardiomyopathy or arrhythmia gene. The genomes of SDY cases, but not controls, were enriched for rare, damaging variants in epilepsy, cardiomyopathy and arrhythmia-related genes. A greater number of rare epilepsy genetic variants correlated with younger age at death.Conclusions While damaging cardiomyopathy and arrhythmia genes are recognized contributors to SDY, we also observed an enrichment in epilepsy-related genes in the SDY cohort, and a correlation between rare epilepsy variation and younger age at death. These findings emphasize the importance of considering epilepsy genes when evaluating SDY.Competing Interest StatementMY serves as consultant to Fabric Genomics Inc. and has received consulting fees and stock grants from Fabric Genomics Inc. EMM is a consultant for Amgen, Avidity, AstraZeneca, Cytokinetics, PepGen, Pfizer, Tenaya Therapeutics, Stealth BioTherapeutics, Invitae, and is the founder of Ikaika Therapeutics.Funding StatementThis work was supported by grants from the National Institutes of Health (U01HL131914, U01HL131698, HL128075, and U01HL131911), the American Heart Association Strategically Focused Research Network on Arrhythmia and Sudden Cardiac Death and Career Development Award (MJP). This study was made possible by the Sudden Death in the Young Case Registry, a collaboration between the National Heart, Lung, and Blood Institute and National Institute of Neurologic Disorders and Stroke of the National Institutes of Health and the Centers for Disease Control and Prevention, and its Data Coordinating Center at the Michigan Public Health Institute and biorepository at the University of Michigan.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SDY Case Registry aggregated information form 13 participating states and jurisdictions in collaboration with public health agencies, including medical examiner offices. Clinical data were collected via the US National Child Death Review Case Reporting System. The Institutional Review Board (IRB) at the Office of Research Integrity at the Michigan Public Health Institute (MPHI) provided ethical approval for the study (initial approval 2015 with subsequent annual renewals). The MPHI was the central IRB, and for those jurisdictions who did not rely on the central IRB, local IRBs provided approval for the study. Parents/ next of kin provided written informed consent for research use of the decedent's DNA and linked information to create a research repository. The MPHI also served as the Data Coordinating Center (DCC) for the SDY Case Registry. Biospecimens for DNA were obtained at autopsy. All data was deidentified for the analysis performed in this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesBoth phenotype (where available) and sequence data will be available via dbGAP after publication or by reasonable request to the corresponding author. Relevant data and scripts will be made available upon request to the corresponding author.SDYSudden death in the youngNIHNational Instistutes of HealthCDCCenter for Disease ControlSIDSSudden infant death syndromeSUIDSudden unexprected infant deathSUDEPSudden unexplained death in epilepsyP/LPPathogenic or likely pathogenicSUDPSudden unexpected death in pediatricsGSGenome sequencingVUSVariant of unknown significancegnomADGenome aggregation databasePCAPrincipal component analysisEIEEEarly infantile epileptic encephalopathyOMIMOnline Mendelian inheritance in manCMAR1CardioMyopathy and Arrhythmia panel 1CMAR2CardioMyopathy and Arrhythmia panel 2AIArtificial intelligenceHPOHuman phenotype ontologyFDRFalse discovery rate